Otsuka wins FDA approval for Simtriyo ADHD treatment in adults, children 6+

Reuters2026/07/25 01:25

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Otsuka won FDA clearance for SIMTRIYO (centanafadine) to treat ADHD in adults, children aged 6+ weighing at least 20 kg.
Drug is positioned as the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for ADHD.
US launch is slated for later this year, pending DEA scheduling.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otsuka Holdings Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607242125BIZWIRE_USPR_____20260724_BW968244) on July 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Otsuka wins FDA approval for Simtriyo ADHD treatment in adults, children 6+

You may also like

Crypto prices